JP2008536480A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536480A5
JP2008536480A5 JP2007556309A JP2007556309A JP2008536480A5 JP 2008536480 A5 JP2008536480 A5 JP 2008536480A5 JP 2007556309 A JP2007556309 A JP 2007556309A JP 2007556309 A JP2007556309 A JP 2007556309A JP 2008536480 A5 JP2008536480 A5 JP 2008536480A5
Authority
JP
Japan
Prior art keywords
marker
cancer
subject
sample
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007556309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536480A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005584 external-priority patent/WO2006089087A2/en
Publication of JP2008536480A publication Critical patent/JP2008536480A/ja
Publication of JP2008536480A5 publication Critical patent/JP2008536480A5/ja
Pending legal-status Critical Current

Links

JP2007556309A 2005-02-17 2006-02-17 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法 Pending JP2008536480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65422705P 2005-02-17 2005-02-17
US69006405P 2005-06-13 2005-06-13
PCT/US2006/005584 WO2006089087A2 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Publications (2)

Publication Number Publication Date
JP2008536480A JP2008536480A (ja) 2008-09-11
JP2008536480A5 true JP2008536480A5 (https=) 2009-03-26

Family

ID=36917075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556309A Pending JP2008536480A (ja) 2005-02-17 2006-02-17 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法

Country Status (5)

Country Link
US (1) US8168602B2 (https=)
EP (1) EP1855727A2 (https=)
JP (1) JP2008536480A (https=)
CA (1) CA2595699A1 (https=)
WO (1) WO2006089087A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991701A4 (en) * 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
US8372582B2 (en) * 2006-08-01 2013-02-12 Joslin Diabetes Center, Inc. Methods of modulating metabolic memory
US20100008910A1 (en) * 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
EP2164990A4 (en) * 2007-05-21 2011-02-23 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
JP2011001267A (ja) * 2007-10-17 2011-01-06 Univ Of Tokyo 大腸癌治療薬
JP5586164B2 (ja) * 2009-04-06 2014-09-10 聡明 渡邉 潰瘍性大腸炎患者の癌化リスクを決定する方法
WO2010121370A1 (en) * 2009-04-20 2010-10-28 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
CA2789494C (en) 2010-02-10 2021-08-17 The Regents Of The University Of California Salivary biomarkers for lung cancer detection
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US8709718B1 (en) 2011-02-12 2014-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method of treating lung cancer
CA2852098C (en) * 2011-10-21 2023-05-02 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
EP4361609A3 (en) * 2012-02-03 2024-07-17 California Institute of Technology Signal encoding and decoding in multiplexed biochemical assays
AU2015236054B2 (en) * 2014-03-25 2019-11-21 Five3 Genomics, Llc Systems and methods for RNA analysis in functional confirmation of cancer mutations
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
EP3405185A4 (en) * 2016-01-19 2019-09-18 Thomas Blumenthal BIOMARKERS FOR DOWN SYNDROME AND USES THEREOF
EP3203413A1 (en) * 2016-02-08 2017-08-09 Ecole Polytechnique Federale De Lausanne (Epfl) Method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
CN109125729A (zh) * 2018-09-06 2019-01-04 苏州吉玛基因股份有限公司 与非小细胞肺癌诊疗相关的基因BRD9及其siRNAs和应用
JP7262736B2 (ja) * 2018-10-31 2023-04-24 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
EP4005634A4 (en) * 2019-07-24 2023-11-08 Tohoku University Chimeric molecule, pharmaceutical composition, method for cleaving target nucleic acid, and kit for target nucleic acid cleavage or diagnosis
CN110317876A (zh) * 2019-08-02 2019-10-11 苏州宏元生物科技有限公司 一组染色体不稳定变异在制备诊断多发性骨髓瘤、评估预后的试剂或试剂盒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
EP1774043A4 (en) * 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER

Similar Documents

Publication Publication Date Title
JP2008536480A5 (https=)
US20200232045A1 (en) Methods of identifying individuals at increased risk of lung cancer
Chernock et al. Detection and significance of human papillomavirus, CDKN2A (p16) and CDKN1A (p21) expression in squamous cell carcinoma of the larynx
JP2023118802A (ja) 非アルコール性脂肪性肝疾患、非アルコール性脂肪性肝炎、及び/又は肝線維症の非侵襲的診断
JP2015521050A5 (https=)
JP6755240B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
JP2017184729A (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ4d7
JP2008512984A5 (https=)
JP2013541339A5 (https=)
US20220136061A1 (en) Treatment and detection of melanoma
JP2017519522A (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
WO2017039359A1 (ko) 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법
JP2018504909A5 (https=)
JP2008514209A (ja) 癌マーカー
KR20170141951A (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
CN110016504A (zh) CDR1as在神经管畸形产前筛查中的应用、神经管畸形产前筛查的产品和方法
EP2710143A1 (en) Method for determining whether a subject is at risk of having or developing a chronic kidney disease
CN115807082B (zh) lncRNA LINREP在胶质瘤诊断、预后和治疗中的应用
KR20220039065A (ko) 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커
JP2012526543A5 (https=)
US20250327805A1 (en) Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
ES2528672A1 (es) Neurofilina-1 (NRP-1) urinaria como marcador pronóstico de nefritis y nefritis lúpica
CN105408498A (zh) 基因表达生物标志物及其用于潜在需要hdac抑制剂治疗的患者中的诊断和预后应用的用途
JP7610265B2 (ja) 大腸癌診断用マーカー、大腸癌の診断を補助する方法、大腸癌の診断のためにデータを収集する方法、大腸癌の診断用キット、大腸癌治療薬、大腸癌の治療方法、大腸癌の診断方法
KR102691995B1 (ko) 미만형 위암의 예후 진단 마커